Navigation Links
Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
Date:12/11/2008

TUSTIN, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that Thomas A. Waltz, M.D., chairman of its Board of Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been a director of Peregrine since 2004 and was chairman since 2005. At the time of his death, Dr. Waltz served on Peregrine's Audit Committee, Compensation Committee and Nominating Committee.

"The sudden loss of our business colleague and friend Tom Waltz brings sadness to the entire Peregrine family," said Steven W. King, president and CEO of Peregrine. "Our deepest sympathies go out to Tom's family and to all who knew him well. Tom's distinguished career as a top neurosurgeon and healthcare executive was matched by his generosity and spirit. His medical and healthcare expertise was of significant value to Peregrine and his talents, wisdom and guidance will be missed."

Dr. Waltz was a neurosurgeon and a senior consultant in Neurosurgery at the Scripps Clinic in La Jolla, California. He formerly was chairman and CEO of the Scripps Clinic and president of the Scripps Clinic Medical Group. Dr. Waltz also served on the Board of Genoptix Inc. and Premera Blue Cross of Washington and Alaska. He received his undergraduate degree from the University of Cincinnati, his M.D. from Vanderbilt University and his neurosurgical training at Baylor College of Medicine. Dr. Waltz also had training in Neurology at The National Hospital for Neurological Diseases and in Neuropathology at Oxford University, both in the U.K.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                Media
    info@peregrineinc.com                    Barbara Lindheim
    (800) 987-8256                           (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
2. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
5. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
6. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
8. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
9. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
10. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):